[摘要] 目的：准确评价微小RNA-29（miRNA-29）对恶性肿瘤的诊断价值。方法：检索3 个英文数据库PubMed、Embase 和Web of Science 以及2 个中文数据库中国知网（CNKI）和万方数据（Wanfang Data），检索自各数据库建立时间起至2018 年9 月15日miRNA-29 的文献资料，检索词包括miRNA-29（miR-29）、肿瘤、癌、血清、血浆、诊断、tumor、cancer、carcinoma、serum、plasma、diagnosis 等，用诊断准确性研究的质量评价-2（QUADAS-2）工具对纳入文献进行质量控制，用Stata12.0 统计学软件计算合并灵敏度、特异度、阳性似然比、阴性似然比及诊断比值比，采用Meta 回归分析及亚组分析探究异质性来源。结果：从1 172 篇与肿瘤、miR-29 相关的文献中筛选出20 篇文献，其合并灵敏度为0.76（95%CI：0.68~0.83），合并特异度为0.83（95%CI：0.74~0.89），合并阳性似然比（PLR）为4.5（95%CI：2.70~7.40），合并阴性似然比（NLR）为0.28（95%CI：0.20~0.41），诊断优势比（DOR）为16（95%CI：7~35），受试者工作特征曲线下面积（AUC）为0.86（95%CI：0.83~0.89）。血浆标本的合并特异度显著高于血清标本（P<0.01）。miR-29 对乳腺癌、胰腺癌诊断价值较高（DOR=101.52、11.22），对结直肠癌、非小细胞性肺癌诊断价值较低（DOR=5.05、6.57）；miR-29b 对恶性肿瘤诊断价值较高（DOR=60.91）。未发现显著性发表偏倚（P>0.05）。结论：miR-29 对恶性肿瘤有良好的灵敏度与特异度，具有潜在的诊断价值。

[Abstract] Objective: To determine the potential diagnostic value of miRNA-29 (miR-29) for malignant tumor. Methods: A systematic search of literature regarding miR-29 was performed in three English databases (PubMed, Web of Science, and Embase) and two Chinese databases (Chinese National Knowledge Infrastructure [CNKI] and WanFang). The retrieval was ended until September 15,2018. Search terms included miRNA-29 (miR-29), tumor, cancer, serum, plasma, diagnosis, etc. Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was carried out to evaluate the quality of the selected articles. STATA12.0 was used to calculate the combined sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR). Subgroup analysis and Meta-regression analysis were carried out to explore the origin of heterogeneity. Results: Twenty eligible articles were selected from 1 172 literatures related to tumors and miR-29. The combined sensitivity was 0.76 (95%CI: 0.68-0.83), combined specificity was 0.83 (95%CI: 0.74-0.89), combined PLR was 4.5 (95%CI: 2.7-7.4), combined NLR was 0.28 (95%CI: 0.20-0.41), DOR was 16 (95%CI: 7-35), and the AUC was 0.86 (95%CI: 0.83-0.89). The combined specificity of plasma samples was higher than that of serum samples, and the difference was statistically significant (P<0.01). There was a higher diagnostic value of miR-29 for breast cancer and pancreatic cancer (DOR=101.52, 11.22), but lower diagnostic value for colorectal cancer and non-small cell lung cancer (DOR=5.05, 6.57); miR-29b showed a high diagnostic value for cancer (DOR=60.91). The publication bias was not obvious in this study (P>0.05). Conclusion: This systematic review and Meta-analysis suggests that miR-29 family is a potential biomarker in the diagnosis of cancers with great sensitivity and specificity.